Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects'
October 07, 2016 at 10:45 AM EDT
H.C. Wainwright has started coverage of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) with a Buy rating and $26 price target on potential ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.